Copyright
©The Author(s) 2017.
World J Gastroenterol. Dec 28, 2017; 23(48): 8512-8525
Published online Dec 28, 2017. doi: 10.3748/wjg.v23.i48.8512
Published online Dec 28, 2017. doi: 10.3748/wjg.v23.i48.8512
Figure 7 Effects of anti-miR-214 and miR-301a mimic on the astragaloside IV-induced inhibition of proliferation-, migration- and invasion-promoting capacities of the gastric cancer-associated fibroblasts.
The GCAFs were transfected with 50 nmol/L 214-NC, anti-miR-214, 301a-NC or miR-301a mimic, or co-transfected with 50 nmol/L 214-NC and 50 nmol/L 301a-NC or 50 nmol/L anti-miR-214 and 50 nmol/L miR-301a mimic. After 48 h of transfection, the cells were treated with vehicle control or 40 μmol/L astragaloside IV; conditioned media were prepared to culture BGC-823 cells, whose proliferation (A), migration (B) and invasion (C) capacities were then measured. Data are plotted as mean ± SD of three separate experiments. aP < 0.05 and bP < 0.01.
- Citation: Wang ZF, Ma DG, Zhu Z, Mu YP, Yang YY, Feng L, Yang H, Liang JQ, Liu YY, Liu L, Lu HW. Astragaloside IV inhibits pathological functions of gastric cancer-associated fibroblasts. World J Gastroenterol 2017; 23(48): 8512-8525
- URL: https://www.wjgnet.com/1007-9327/full/v23/i48/8512.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i48.8512